Fuso Chemical (4368) Q2 2026 earnings summary

Executive summary

• Achieved record-high net sales and operating profit for the half-year ended September 30, 2025, with net sales up 8.5% year-over-year to ¥37,705 million and operating profit up 19.7% to ¥9,746 million.

• Profit attributable to owners of parent rose 22.7% to ¥6,879 million; comprehensive income increased 41.6% year-over-year to ¥7,062 million.

• Significant contributions from Electronic Materials & Functional Chemicals, driven by semiconductor demand and new facility ramp-ups.

• Life Science segment faced margin pressure from price declines and yen appreciation, but maintained market share through price revisions and new applications.

Financial highlights

• Gross profit for the six months was ¥14,831 million, up from ¥12,915 million year-over-year.

• EBITDA reached ¥14,328 million, up 20.9% year-over-year.

• Earnings per share for the period were ¥195.12, compared to ¥159.09 in the prior year.

• Overseas sales accounted for 53.5% of total, with strong growth in Asia and North America.

Outlook and guidance

• Full-year forecast for FY03/2026 projects net sales of ¥75,500 million, operating profit of ¥17,500 million, and profit attributable to owners of parent of ¥12,200 million.

• Earnings per share for the full year are forecast at ¥346.04.

• Dividend forecast raised to ¥82 per share, reflecting a progressive dividend policy.

• Semiconductor market recovery and AI-driven demand expected to continue supporting growth.